Please try another search
Aelis Farma SA is a France-based company that is specialized in the research and development of drugs for the treatment of disorders of Central Nervous System (CNS). The Company provides two products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis, and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome). It offers viable treatments for certain pathological conditions linked to hyperactivity of the CB1 receptor, the main receptor of the endocannabinoid system. It provides advanced drug AEF0117, to combat the harmful effects of cannabis and in particular Cannabis Use Disorders (CUD) which is the current definition of cannabis addiction in the diagnostic manual reference DSM-5. The Company operates a Research and Development (R&D) platform, which enables the Company to discover drug candidates that act as specific modulators of target receptor signaling.
Name | Age | Since | Title |
---|---|---|---|
Anders Gersel Pedersen | 72 | 2020 | Independent Chairman of the Board |
Karina Hansen | 50 | 2022 | Independent Director |
Daniele Piomelli | - | - | Member of Scientific Advisory Board |
Markus Heilig | - | - | Member of Scientific Advisory Board |
Irina Staatz-Granzer | 63 | 2022 | Independent Director |
Karen Linehan | 64 | 2022 | Independent Director |
Francois Thomas | 66 | 2022 | Censor |
Pier Vincenzo Piazza | 62 | 2017 | CEO & Director |
Brahim Guetarni | 52 | 2021 | Director |
Keith Humphreys | - | - | Member of Scientific Advisory Board |
Robert C. Malenka | - | - | Chairman of the Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review